JP2011530607A5 - - Google Patents

Download PDF

Info

Publication number
JP2011530607A5
JP2011530607A5 JP2011523078A JP2011523078A JP2011530607A5 JP 2011530607 A5 JP2011530607 A5 JP 2011530607A5 JP 2011523078 A JP2011523078 A JP 2011523078A JP 2011523078 A JP2011523078 A JP 2011523078A JP 2011530607 A5 JP2011530607 A5 JP 2011530607A5
Authority
JP
Japan
Prior art keywords
lower alkyl
phenyl
substituted
amino
pyrimidylaminobenzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011523078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530607A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/053358 external-priority patent/WO2010019540A1/en
Publication of JP2011530607A publication Critical patent/JP2011530607A/ja
Publication of JP2011530607A5 publication Critical patent/JP2011530607A5/ja
Pending legal-status Critical Current

Links

JP2011523078A 2008-08-13 2009-08-11 肺動脈高血圧の治療 Pending JP2011530607A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8838208P 2008-08-13 2008-08-13
US61/088,382 2008-08-13
US16450109P 2009-03-30 2009-03-30
US61/164,501 2009-03-30
PCT/US2009/053358 WO2010019540A1 (en) 2008-08-13 2009-08-11 Treatment of pulmonary arterial hypertension

Publications (2)

Publication Number Publication Date
JP2011530607A JP2011530607A (ja) 2011-12-22
JP2011530607A5 true JP2011530607A5 (cg-RX-API-DMAC7.html) 2012-09-27

Family

ID=41137217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011523078A Pending JP2011530607A (ja) 2008-08-13 2009-08-11 肺動脈高血圧の治療

Country Status (16)

Country Link
US (1) US20110190313A1 (cg-RX-API-DMAC7.html)
EP (1) EP2315592A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011530607A (cg-RX-API-DMAC7.html)
KR (1) KR20110053354A (cg-RX-API-DMAC7.html)
CN (1) CN102123711A (cg-RX-API-DMAC7.html)
AU (1) AU2009282104A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917491A2 (cg-RX-API-DMAC7.html)
CA (1) CA2732789A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011000295A1 (cg-RX-API-DMAC7.html)
IL (1) IL210922A0 (cg-RX-API-DMAC7.html)
MA (1) MA32617B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011001668A (cg-RX-API-DMAC7.html)
NZ (1) NZ590839A (cg-RX-API-DMAC7.html)
RU (1) RU2011109078A (cg-RX-API-DMAC7.html)
TW (1) TW201010999A (cg-RX-API-DMAC7.html)
WO (1) WO2010019540A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671029A1 (en) 2009-06-30 2010-12-30 James S. Baldassarre Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
JP6799201B2 (ja) * 2013-07-31 2020-12-16 アヴァリン ファーマ インク. エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
AU2017348354B2 (en) 2016-10-27 2023-06-15 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
WO2019157337A1 (en) * 2018-02-08 2019-08-15 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
CN114514016A (zh) 2019-05-16 2022-05-17 埃渃维特治疗学公司 伊马替尼调配物、制造和其用途
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
WO2021108303A1 (en) * 2019-11-25 2021-06-03 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
AU2021339756A1 (en) * 2020-09-11 2023-04-13 Pulmosim Therapeutics Llc Compositions and methods for treating or preventing pulmonary hypertension
JP2023550407A (ja) 2020-11-17 2023-12-01 ユナイテッド セラピューティクス コーポレイション 肺高血圧向けの吸入式イマチニブ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003272007A1 (en) * 2002-10-25 2004-05-13 The Administrators Of The Tulane Educational Fund Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
MX2007009135A (es) * 2005-01-28 2007-09-06 Novartis Ag Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulacion de la actividad de la cinasa tie-2.
KR101519311B1 (ko) * 2005-05-02 2015-05-11 노파르티스 아게 과호산구성 증후군을 위한 피리미딜아미노벤즈아미드 유도체
CA2629132C (en) * 2005-12-06 2014-05-27 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
US20100048539A1 (en) * 2006-11-03 2010-02-25 Irm Llc Compounds and compositions as protein kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2011530607A5 (cg-RX-API-DMAC7.html)
USRE49556E1 (en) Compounds and compositions as protein kinase inhibitors
US11952386B2 (en) N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
US10774065B2 (en) 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US9815813B2 (en) 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
RU2011109078A (ru) Лечение легочной артериальной гипертензии
RU2011137399A (ru) Гетероциклическое производное
RU2012147511A (ru) Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза
JP2007509106A5 (cg-RX-API-DMAC7.html)
RS57177B1 (sr) Derivati benzamida za inhibiranje aktivnosti abl1, abl2 i bcr-abl1
AR079029A1 (es) Derivados de pirimidil-amino-benzamida para tratar trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
JP2009532438A5 (cg-RX-API-DMAC7.html)
RU2012120901A (ru) Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r
RU2011105059A (ru) Применение производных пиримидиламинобензамида для лечения фиброза
JP2009537606A5 (cg-RX-API-DMAC7.html)
CN113543784A (zh) 用于治疗或预防癌症的喹啉衍生物
EP2437745A1 (en) Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms
RU2008127264A (ru) Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
RU2007132255A (ru) Применение пиримидиламинобензамидов для лечения заболеваний, чувствительных к модуляции активности киназы tie-2
RU2007144530A (ru) Применение производных пиримидиламинобензамида для лечения системного мастоцитоза
JP2012519668A5 (cg-RX-API-DMAC7.html)
US20110281813A1 (en) Method of treating c-kit positive relapsed acute myeloid leukemia
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
JP2009501765A5 (cg-RX-API-DMAC7.html)
RU2007135284A (ru) Фармацевтические комбинации ингибиторов киназ bcr-abl и raf